An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A person in their early 20s with hypothyroidism, possibly “seronegative” Hashimoto’s (meaning the usual thyroid autoantibodies are absent), asked whether a peptide called SS-31 would help their fatigue and what other peptides on their list might do. They’re looking for practical guidance about whether these experimental peptides are likely to be useful and safe for someone young with thyroid-related fatigue. SS-31 (also called elamipretide in some studies) is a small molecule that’s designed to go into cells’ energy factories, the mitochondria, and protect them from damage. In plain terms: it’s supposed to help cells make energy more efficiently and resist stress. That’s why researchers are interested in it for conditions where cells seem tired or stressed. SS-31 is still experimental for most uses; some early trials have been in rare mitochondrial diseases or heart conditions, not routine hypothyroidism. What the research actually shows is limited and not directly about typical hypothyroidism. Most clinical data on SS-31 come from small trials in specific diseases or from laboratory and animal studies. Those studies sometimes show improvements in cellular markers or symptoms in particular contexts, but they don’t prove SS-31 fixes fatigue from thyroid problems. There’s no large, robust trial showing SS-31 helps people with Hashimoto’s or seronegative autoimmune thyroiditis feel less tired. So the claim “SS-31 will help your hypothyroid fatigue” is not supported by solid evidence right now. Why this matters: fatigue is a common and frustrating symptom of hypothyroidism, and it’s reasonable to look for additional treatments. A drug that safely improves cell energy could, in theory, help. But because SS-31 hasn’t been proven for thyroid-related fatigue, jumping to experimental peptides risks cost, side effects, and delayed attention to proven measures—like making sure thyroid hormone levels are optimized, checking for other causes of fatigue (sleep, iron levels, vitamin D, mental health), and working with a doctor. People who are young and otherwise healthy should be cautious about unproven therapies. Caveats and risks are important. SS-31 is not an approved treatment for hypothyroidism; its safety profile outside research settings isn’t well established. Experimental peptides on your list (MOTS-c, thymosin alpha-1, kisspeptin-10, epitalon, DSIP, selank, etc.) vary widely in what they do, and most lack solid clinical evidence for treating hypothyroid fatigue. Some can affect hormones, immune responses, or mood—so they could have unexpected effects or interact with your thyroid medication. Regulatory status, purity, dosing, and long-term safety are often unknown for these products when bought outside clinical trials. If you’re considering any of them, discuss it with an endocrinologist and avoid self-experimenting with unregulated sources. Bottom line: SS-31 is an interesting experimental mitochondrial drug, but there’s no strong evidence it will relieve hypothyroid-related fatigue. Focus first on established checks and treatments with your doctor before considering experimental peptides, and be cautious about safety and sourcing.
Source: r/Peptides